share_log

Goldman Sachs Maintains Buy on Prometheus Biosciences, Raises Price Target to $144

Goldman Sachs Maintains Buy on Prometheus Biosciences, Raises Price Target to $144

高盛维持对普罗米修斯生物科学的买入,将目标价上调至144美元
Benzinga Real-time News ·  2023/01/31 09:23

Goldman Sachs analyst Chris Shibutani maintains Prometheus Biosciences (NASDAQ:RXDX) with a Buy and raises the price target from $117 to $144.

高盛分析师Chris Shibutani维持普罗米修斯生物科学公司(纳斯达克:RXDX)的买入,并将目标价从117美元上调至144美元。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发